Jaguar Health, Inc. (JAGX)
Nasdaq · Healthcare · Biotechnology
$4.73+29.24%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $9.2M
- 52-week range
- $2.35 – $1,267.88
- 52-week change
- −99.67%
- EPS (trailing)
- −$4,012.65
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $11.5M (−1.52%)
- Net income
- −$54K
- Operating margin
- −398.8%
- Diluted EPS
- −$22.97
From the company’s annual report on SEC EDGAR.
About Jaguar Health, Inc.
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea.
Headquarters: San Francisco, United States · 47 employees · jaguar.health